Seoulin Bioscience Co

Seoulin Bioscience Co EBIT Margin

The EBIT Margin (Operating Margin) of Seoulin Bioscience Co (038070.KQ) as of Nov 4, 2026 is 0.90 %. In the previous year, EBIT Margin (Operating Margin) was 0.13 % — a change of 572.87% (higher).

EBIT Margin

0.90 %

YoY

572.87%

Last updated:

EBIT Margin (Operating Margin) of Seoulin Bioscience Co is 2025 0.90 % . EBIT Margin (Operating Margin) of Seoulin Bioscience Co was 2024 0.13 % . It decreases by 572.87% higher compared to the previous year.

For Seoulin Bioscience Co, the operating (EBIT) margin of 0.9% is down versus 7.5% a few years ago.

The Seoulin Bioscience Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
3.50 KRW
Jan 1, 2019
1.47 KRW
Jan 1, 2020
6.87 KRW
Jan 1, 2021
7.51 KRW
Jan 1, 2022
8.29 KRW
Jan 1, 2023
0.18 KRW
Jan 1, 2024
0.13 KRW
Jan 1, 2025
0.90 KRW
The Seoulin Bioscience Co EBIT Margin history
YEAREBIT MarginYoY
0.90 %+572.87%
0.13 %-27.86%
0.18 %-97.77%
8.29 %+10.51%
7.51 %+9.27%
6.87 %+367.03%
1.47 %-57.99%
3.50 %+48.83%
2.35 %-51.24%
4.82 %+14.59%
4.21 %-41.26%
7.17 %+6,974.56%
0.10 %-2.53%
0.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Seoulin Bioscience Co Stock analysis

What does Seoulin Bioscience Co do? SeouLin Bioscience Co., Ltd. generates revenue through the development and supply of reagents, including DNA chips for gene therapy, clinical diagnosis, organ transplantation, and biopsy, as well as stem cells for treating incurable diseases and Alzheimer's disease. The company markets these products under its brand MyLab and imports bio research equipment from Thermo Fisher, Affymetrix, and Sarstedt for domestic sales. Additionally, SeouLin Bioscience operates a real estate rental business to diversify its income streams. The primary customers for MyLab reagents and stem cell therapies are healthcare providers, research institutions, and medical facilities requiring advanced diagnostic and therapeutic solutions. Domestic market distribution of imported bio research equipment from Thermo Fisher, Affymetrix, and Sarstedt targets laboratories and hospitals seeking high-quality research tools. The real estate rental business serves commercial tenants in Seongnam, Gyeonggi-Do, where the company is headquartered. SeouLin Bioscience focuses on the lifescience sector, specifically targeting applications in gene therapy, clinical diagnostics, and regenerative medicine. Its product segments include DNA chips, stem cells, and next-generation biotechnology drugs, all under the MyLab brand. The company leverages strategic imports of bio research equipment to meet domestic demand for specialized laboratory tools. Seoulin Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seoulin Bioscience Co stock

EBIT Margin (Operating Margin) of Seoulin Bioscience Co is 0.90 % in 2025.

EBIT Margin (Operating Margin) of Seoulin Bioscience Co changed from 0.13 % to 0.90 %, representing a 572.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Seoulin Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Seoulin Bioscience Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Seoulin Bioscience Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Seoulin Bioscience Co